Korro Bio, Inc. (NASDAQ: KRRO) has announced a significant regulatory filing for the initiation of the first-in-human study of KRRO-110 and the formation of a Clinical Advisory Board (CAB) comprised of distinguished lung and liver experts. The regulatory filing for a Phase 1/2 clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) has been submitted to the Australian Bellberry Human Research Ethics Committee (HREC).
The first participant dosing for the Phase 1/2 study of KRRO-110 is anticipated in the first quarter of 2025, with an interim data readout expected in the second half of 2025, and completion of the study anticipated in 2026.
KRRO-110 is the first RNA editing oligonucleotide product candidate from Korro’s proprietary RNA editing platform, Oligonucleotide Promoted Editing of RNA (OPERA™). It is designed to co-opt an endogenous enzyme, adenosine deaminase acting on RNA (ADAR), to edit the "A" variant on serpina1 RNA, repair an amino acid codon, and restore secretion of normal AAT protein. This repair has the potential to clear protein aggregates from within liver cells and preserve lung function by providing an adequate amount of normal AAT protein.
The Clinical Advisory Board (CAB) has been assembled to help guide the clinical development strategy for KRRO-110 and includes distinguished members such as Professor Daniel Chambers from the University of Queensland and the Prince Charles Hospital in Australia, Dr. Monica Goldklang from Columbia University in New York, Professor Noel G. McElvaney from the Royal College of Surgeons in Ireland, Professor Pavel Strnad from the University Hospital Aachen in Germany, Professor Jeffrey Teckman from Saint Louis University in the USA, and Professor Alice M. Turner from the University of Birmingham Institute of Applied Health Research in the UK.
Korro's CEO and President, Ram Aiyar, expressed immense pride in the progress made since the nomination of KRRO-110 for AATD in December 2023, highlighting the company's robust pipeline of fully owned and partnered programs. With a strong balance sheet to support the completion of the Phase 1/2 study and to advance the next set of programs, Aiyar is excited to see the potential of the OPERA™ platform realized.
Korro is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. As a result of these announcements, the company's shares have moved 3.5% on the market, and are now trading at a price of $60.19. Check out the company's full 8-K submission here.
